Literature DB >> 18544950

Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid.

Kinuyo Hatanaka1, Masatoshi Kudo, Yasunori Minami, Taisuke Ueda, Chie Tatsumi, Satoshi Kitai, Shunsuke Takahashi, Tatsuo Inoue, Satoru Hagiwara, Hobyung Chung, Kazuomi Ueshima, Kiyoshi Maekawa.   

Abstract

OBJECTIVE: To clarify the value of contrast-enhanced harmonic ultrasonography (US) with Sonazoid, a second-generation US contrast agent, in the differential diagnosis of liver tumors compared to dynamic CT.
METHODS: A total of 249 hepatic nodules in 214 patients were studied; these included 177 hepatocellular carcinomas (HCCs), 42 liver metastases, 20 liver hemangiomas, 6 dysplastic nodules and 4 focal nodular hyperplasias (FNHs). After the injection of Sonazoid, nodules were scanned using real-time contrast-enhanced harmonic US in the vascular phases, i.e. the early and late vascular phases, and the Kupffer phase.
RESULTS: Six enhancement patterns were identified to be significant for the differential diagnosis of hepatic tumors. In HCCs, the presence of intratumoral vessels supplied from the periphery and fast washout (sensitivity, 96.6%; specificity, 94.4%) were the most typical characteristics. In metastases, the presence of rim-like enhancement with peripheral tumor vessels (sensitivity, 88.1%; specificity, 100%) was the typical pattern. In hemangiomas, the presence of intratumoral hypoperfusion images with globular or cotton wool-like pooling, which continue to the late vascular phase (sensitivity, 90.0%; specificity, 99.6%), was typical. In dysplastic nodules, the presence of portal enhancement without arterial supply in the early vascular phase and the presence of intratumoral uptake in the Kupffer phase (sensitivity, 83.3%; specificity, 100%) were the most typical patterns. In FNHs, the presence of a spoke-wheel pattern in the early vascular phase with dense staining in the late vascular phase, and positive uptake within the nodule in the Kupffer phase (sensitivity, 100%; specificity, 100%) were the most typical patterns.
CONCLUSION: Contrast-enhanced harmonic US with Sonazoid allowed intimate vascular and Kupffer imaging and, therefore, is useful for the differential diagnosis of hepatic tumors. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544950     DOI: 10.1159/000122600

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  48 in total

1.  Differentiation of focal liver lesions using three-dimensional ultrasonography: retrospective and prospective studies.

Authors:  Wen Luo; Kazushi Numata; Manabu Morimoto; Akito Nozaki; Michio Ueda; Masaaki Kondo; Satoshi Morita; Katsuaki Tanaka
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

2.  Detection of focal liver lesions in cirrhotic liver using contrast-enhanced ultrasound.

Authors:  Grace Lai-Hung Wong; Hui-Xiong Xu; Xiao-Yan Xie
Journal:  World J Radiol       Date:  2009-12-31

3.  Usefulness of Sonazoid contrast-enhanced ultrasonography for hepatocellular carcinoma: comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images.

Authors:  Keiko Korenaga; Masaaki Korenaga; Matakazu Furukawa; Takahiro Yamasaki; Isao Sakaida
Journal:  J Gastroenterol       Date:  2009-04-23       Impact factor: 7.527

4.  Contrast-enhanced ultrasonography with Sonazoid™ for the evaluation of bowel ischemia.

Authors:  Tomoko Kanzaki; Jiro Hata; Hiroshi Imamura; Noriaki Manabe; Kazuhide Okei; Hiroaki Kusunoki; Tomoari Kamada; Akiko Shiotani; Ken Haruma
Journal:  J Med Ultrason (2001)       Date:  2012-03-13       Impact factor: 1.314

5.  Three cases of angiomyolipoma: diagnostic imaging by contrast-enhanced ultrasonography.

Authors:  Yayoi Yamamoto; Yoshimasa Fujiwara; Seigo Yukisawa; Kiyoshi Matsueda; Masamichi Katori; Keiko Yamada; Atsushi Kohno
Journal:  J Med Ultrason (2001)       Date:  2009-12-29       Impact factor: 1.314

Review 6.  Simulation and navigation liver surgery: an update after 2,000 virtual hepatectomies.

Authors:  Akinori Miyata; Junichi Arita; Yoshikuni Kawaguchi; Kiyoshi Hasegawa; Norihiro Kokudo
Journal:  Glob Health Med       Date:  2020-10-31

Review 7.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

8.  Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma.

Authors:  Tomoki Kobayashi; Hiroshi Aikata; Masahiro Hatooka; Kei Morio; Reona Morio; Hiromi Kan; Hatsue Fujino; Takayuki Fukuhara; Keiichi Masaki; Atsushi Ohno; Noriaki Naeshiro; Takashi Nakahara; Yohji Honda; Eisuke Murakami; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Yoshiiku Kawakami; Hideyuki Hyogo; Shoichi Takahashi; Kazuaki Chayama
Journal:  Eur Radiol       Date:  2015-06-03       Impact factor: 5.315

Review 9.  Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound.

Authors:  Shu-Guang Zheng; Hui-Xiong Xu; Lin-Na Liu
Journal:  World J Radiol       Date:  2014-01-28

10.  Sonazoid-enhanced sonography for guiding radiofrequency ablation for hepatocellular carcinoma: better tumor visualization by Kupffer-phase imaging and vascular-phase imaging after reinjection.

Authors:  Noriyuki Miyamoto; Kazuhide Hiramatsu; Kazuhiko Tsuchiya; Yukihiko Sato; Satoshi Terae; Hiroki Shirato
Journal:  Jpn J Radiol       Date:  2009-06-06       Impact factor: 2.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.